Bone and Mineral Metabolism Disorders
Phase 3 results from the PHREEDOM study demonstrated treatment with tenapanor safely and effectively decreased serum phosphorous in patients with chronic kidney disease on dialysis, according to a press release from Ardelyx Inc.
“These results are very exciting and represent a capstone to our tenapanor clinical development program, which is focused on the development of a new and important therapy for patients with hyperphosphatemia," Mike Raab, president and CEO of Ardelyx, said in the release. "Based on the PHREEDOM data that demonstrate tenapanor as an effective monotherapy, and the previously released AMPLIFY data that demonstrate the benefits of a dual-mechanism approach with tenapanor plus binders in those who require more aggressive phosphate management, it is clear that tenapanor has a role to play in the management of all dialysis patients with hyperphosphatemia.”
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2020 Healio All Rights Reserved.